Email a Friend
To: (email address)
From: (email address)
Email Subject:
Note: (optional)
255 character limit
When it comes to lowering LDL cholesterol, your patients at increased risk may need aggressive treatment to achieve their LDL-C goals.
In this section, you can review LDL cholesterol reduction results and LDL cholesterol goal attainment results from comparative clinical trials in which CRESTOR® (rosuvastatin calcium) was used as an adjunct to diet in adult patients starting statin therapy. The usual starting dose of CRESTOR is 10 mg to 20 mg. CRESTOR 40 mg should be used only for those patients not achieving their LDL-C goal with 20 mg.1
For detailed comparative clinical trial data on LDL-C goal attainment or LDL-C reductions, click on the appropriate tab below.
Click on the "+" and "—" signs to expand and collapse the clinical information.
‡Subject to eligibility. Restrictions apply. Click here for eligibility information.
In high-risk patients in the ECLIPSE trial,
CRESTOR helped more patients achieve LDL-C goal than Lipitor®
(atorvastatin calcium)2
Adapted from the ECLIPSE Trial
In the STELLAR trial in patients with hyperlipidemia or mixed dyslipidemia nearly 9 out of 10 met their LDL-C goal with CRESTOR 20 mg*5
Adapted from the STELLAR Trial
Achievement of LDL-C <100 mg/dL vs atorvastatin in patients with hyperlipidemia or mixed dyslipidemia6
Adapted from the STELLAR Trial
Achievement of LDL-C <100 mg/dL vs simvastatin in patients with hyperlipidemia or mixed dyslipidemia6
Adapted from the STELLAR Trial
Achievement of LDL-C <100 mg/dL vs pravastatin in patients with hyperlipidemia or mixed dyslipidemia6
Adapted from the STELLAR Trial
Next: LDL-C Reductions
Lipitor is a registered trademark of Pfizer Inc.
You may report side effects related to AstraZeneca products by clicking here.